AngioDynamics, Inc. (ANGO) Stock

AngioDynamics, Inc. (ANGO) is a Healthcare stock trading at $15.83 (as of 2026-08-20), with a market capitalization of $654.29M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

AngioDynamics, Inc. designs, manufactures, and sells medical and diagnostic devices used by healthcare professionals for treatment of peripheral vascular disease and vascular access, and in oncology and surgical settings. Its offerings include tissue ablation systems and tract sealant and related catheter and interventional products, used primarily in the United States and internationally.

Understand AngioDynamics, Inc.: how it makes money

AngioDynamics designs, manufactures, and sells medical, surgical, and diagnostic devices for professional healthcare providers, including ablation systems (NanoKnife, solero, radiofrequency) and vascular access and oncology related products, generating revenue primarily from sales of these devices.

Profit and growth appear tied to procedure and installed-base activity, where new platform placements and the existing installed base (for example, Ariane lasers, plus procedure activity metrics) support ongoing clinical use and related sales, while any slowdown in placements can pressure results.

Revenue by segment (latest quarter)
Endovascular$0.1B
MedTech$0.0B
Nanolife$0.0B

Business quality (Weak): The business description and multiple operating metrics help explain demand drivers (placements, installed base, and procedure activity), but the provided segment numbers include pro forma labels, and the latest quarter shows negative operating margin.

Bull case

  • Large installed base for Ariane: Ariane Installed Base Lasers are 370.0 (count), which can support ongoing clinical use.
  • Procedure mix for NanoKnife prostate appears strong: NanoKnife Prostate Procedures Share is 81.0 (percent), with 111.0 NanoKnife Prostate Cases Completed (count).

Bear case

  • Loss-making at the operating level: Operating margin is -16.5% for the latest reported period (2026-02-28).
  • Potential softness in one placement driver: Additions to Auryon Placement and Evaluation Units are 0.0 (USD_B), which could indicate limited momentum in that area.
Valuation — source: SEC EDGAR (first-party)
Price$15.83
Market Cap$654.29M
EV / EBITDA39.0
Price / Book3.83
Price / Sales2.14
FCF Yield-12.0%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$320.17M
Net Margin-11.5%
Revenue Growth (YoY)9.5%
EPS Growth (YoY)6.0%
FCF Growth (YoY)-103.5%
Financial Health — source: SEC EDGAR
Altman Z-Score2.74 (grey)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.6
Industry P/E (Medical Equipment)32.9
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderBlackRock Fund Advisors ($42.40M)
Institutional Holders Tracked10
Congressional Trades (recent)1
Company
SectorHealthcare
IndustryMedical Equipment
CEOJames C. Clemmer
Employees748
CountryUS
IPO Date2004-06-01

Related Companies (Business model: Medical Devices / Life Science Tools; 8 closest by market cap; US-domiciled)

  • Beta Bionics, Inc. (BBNX)
  • SI-BONE, Inc. (SIBN)
  • SS Innovations International, Inc. (SSII)
  • OrthoPediatrics Corp. (KIDS)
  • MiMedx Group, Inc. (MDXG)
  • Delcath Systems, Inc. (DCTH)
  • Cerus Corporation (CERS)
  • Tactile Systems Technology, Inc. (TCMD)
ANGO earnings history · ANGO institutional & insider holders · ANGO KPIs & operating metrics · ANGO financials · ANGO investor presentations & press releases · ANGO SEC filings · ANGO peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-20.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.